Saso Cemerski
Executive Director, Head of Immune Engagers AstraZeneca
Dr. Saso Cemerski is Executive Director and Head of Immune Engagers at AstraZeneca. With a background spanning immunology, oncology, and biologics engineering, he previously held scientific leadership roles at Cue Biopharma, Merck Research Labs, and Bristol‑Myers Squibb. Dr. Cemerski completed his PhD in Immunology at Université Paul Sabatier and conducted postdoctoral research at Washington University School of Medicine.
Seminars
Wednesday 24th June 2026
Revolutionizing Solid Tumor Care by Applying Haematology‑Driven Insights to Optimize Clinical Delivery and Dosing
5:30 pm
- Extracting key lessons from haematology’s shift in delivery models, including the transition from traditional IV regimens to streamlined subcutaneous approaches, and understanding how these changes have improved patient experience, clinic efficiency, and therapeutic consistency
- Leveraging haematology’s established frameworks for step‑up dosing, toxicity mitigation, and response monitoring, exploring how these principles can be adapted to solid tumor therapies to improve safety, manage CRS and related immune toxicities, and support broader outpatient administration
- Examining real‑world evidence and clinical learnings from haematology agents such as bispecifics and T‑cell engagers, and assessing how these insights are shaping the clinical deployment, exposure management, and dose optimization of emerging solid‑tumor agents, highlighting Tarlatamab and next‑generation molecules as examples of iterative improvement driving enhanced patient outcomes
Wednesday 24th June 2026
Opening Panel Discussion: Reflecting on Past Successes & Future Challenges Across the T-Cell Engager Landscape
9:00 am
- Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
- Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
- Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies
Wednesday 24th June 2026
Navigating the Early Clinical Hurdles of T-Cell Engagers in Solid Tumors
10:00 am
- Exploring strategies for widening the therapeutic index in solid tumors, focusing of affinity tuning of CD3 arm and the implementation of logic-gated architectures to protect healthy tissues
- Overcoming physical and metabolic barriers of solid tumor core by integrating costimulatory signals
- Utilizing context-dependent engagers that are only active in hypoxic or acidic conditions
